Business
NeuroOne® Medical Technologies Corporation Announces First Human Commercial Use of its Evo™ Cortical Electrode at Mayo Clinic
EDEN PRAIRIE, Minn., Dec. 3, 2020 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on
About this update from Neuroone Medical Technologies Corporation
[{"type":"text","content":"EDEN PRAIRIE, Minn., Dec. 3, 2020 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the first human commercial use of its Evo Cortical Electrode at Mayo Clinic in Rochester, Minnesota.\n\n \n \n \n \n \n \n\n \nThe procedure was performed by Jamie Van Gompel, M.D., from November 23rd through November 27th on a patient that had drug resistant epilepsy and utilized the NeuroOne Evo electrode technology to perform recording, functional mapping and stimulation of the brain. Three NeuroOne electrodes were also used in addition to four Ad-Tech Medical electrodes during the procedure. In addition to recording a seizure, the NeuroOne electrodes also recorded evidence of pre-seizure activity which may be critical in developing treatments to prevent the onset of seizures.\nDr. Van Gompel stated, \"Thin film electrode technology has been in development for years and in addition to its thin film, light weight properties, the electrodes also conformed very securely to the brain. The recordings were sharp and clearly noted evidence of pre-seizure activity. We were also able to visualize the brain under CT imaging which was very useful. We are very excited to continue to explore the potential clinical advantages of this technology for our patients,\" said Dr. Van Gompel, one of the co-developers of this technology.\nDave Rosa, president and CEO, NeuroOne, says, \"After years of development it was exciting to witness the initial validation of our Evo cortical electrode technology at Mayo Clinic. We are grateful to all the institutions that helped provide valuable guidance along the way and look forward to making our technology available to a multitude of centers through our distribution and development partner Zimmer Biomet. We hope to add to this line next year with a family of sEEG electrodes that offer a similar feature set as the Evo cortical product portfolio.\" \nEvo Cortical Electrodes, intended for recording, monitoring and stimulating brain tissue for up to 30 days, may have the potential to change the landscape of neurosurgical procedures offering potential benefit to both physicians and patients. The technology utilizes sophisticated automated manufac...